JP2024509911A - 疾患の治療のための方法及び組成物 - Google Patents

疾患の治療のための方法及び組成物 Download PDF

Info

Publication number
JP2024509911A
JP2024509911A JP2023555206A JP2023555206A JP2024509911A JP 2024509911 A JP2024509911 A JP 2024509911A JP 2023555206 A JP2023555206 A JP 2023555206A JP 2023555206 A JP2023555206 A JP 2023555206A JP 2024509911 A JP2024509911 A JP 2024509911A
Authority
JP
Japan
Prior art keywords
abatacept
aldesleukin
formulation
administered
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023555206A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022192536A5 (https=
JP2024509911A5 (https=
Inventor
ハーシュ アペル スタンレー
ファリダール アリレザ
バーマン ハワード
Original Assignee
ザ メソディスト ホスピタル
コヤ セラピューティクス， インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ メソディスト ホスピタル, コヤ セラピューティクス， インク． filed Critical ザ メソディスト ホスピタル
Publication of JP2024509911A publication Critical patent/JP2024509911A/ja
Publication of JPWO2022192536A5 publication Critical patent/JPWO2022192536A5/ja
Publication of JP2024509911A5 publication Critical patent/JP2024509911A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
    • A61N1/36082—Cognitive or psychiatric applications, e.g. dementia or Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Developmental Disabilities (AREA)
  • Psychology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023555206A 2021-03-11 2022-03-10 疾患の治療のための方法及び組成物 Pending JP2024509911A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163159919P 2021-03-11 2021-03-11
US63/159,919 2021-03-11
US202163225846P 2021-07-26 2021-07-26
US63/225,846 2021-07-26
US202263310839P 2022-02-16 2022-02-16
US63/310,839 2022-02-16
PCT/US2022/019748 WO2022192536A1 (en) 2021-03-11 2022-03-10 Methods and compositions for treatment of disease

Publications (3)

Publication Number Publication Date
JP2024509911A true JP2024509911A (ja) 2024-03-05
JPWO2022192536A5 JPWO2022192536A5 (https=) 2025-06-05
JP2024509911A5 JP2024509911A5 (https=) 2025-06-05

Family

ID=83228307

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023555206A Pending JP2024509911A (ja) 2021-03-11 2022-03-10 疾患の治療のための方法及び組成物

Country Status (8)

Country Link
US (1) US20240148827A1 (https=)
EP (1) EP4304624A4 (https=)
JP (1) JP2024509911A (https=)
KR (1) KR20230169147A (https=)
AU (1) AU2022235091A1 (https=)
CA (1) CA3211627A1 (https=)
MX (1) MX2023010455A (https=)
WO (1) WO2022192536A1 (https=)

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013041029A1 (en) * 2011-09-23 2013-03-28 Igenimed Pharmaceuticals Inc. Novel soluble ctla4 variants
JP2013520176A (ja) * 2010-02-19 2013-06-06 ゼンコア インコーポレイテッド 新規ｃｔｌａ４−ｉｇ免疫アドヘシン
US20130251713A1 (en) * 2000-07-03 2013-09-26 Bristol-Myers Squibb Company Methods for treating juvenile rhumatoid arthritis by administering a soluble ctla4 molecule
US20130295092A1 (en) * 2008-12-05 2013-11-07 Als Therapy Development Institute Method for the Treatment of Neurodegenerative Diseases
JP2014510725A (ja) * 2011-03-11 2014-05-01 アシスタンス ピュブリク−オピトー ドゥ パリ 自己免疫関連障害または炎症性障害の治療のための低用量ｉｌ−２の使用
US20140193908A1 (en) * 2011-07-19 2014-07-10 Philogen S.P.A. Sequential antibody therapy
JP2015530984A (ja) * 2012-08-10 2015-10-29 ロシュ グリクアート アーゲー インターロイキン−２融合タンパク質及びそれらの使用
US20160287671A1 (en) * 2013-06-25 2016-10-06 Icm (Institut Du Cerveau Et De La Moelle Épinière Boosting treg cells for treating alzheimer disease and related disorders
CN109999179A (zh) * 2019-05-08 2019-07-12 山东省分析测试中心 低剂量白介素2用于制备治疗阿尔茨海默病药物中的应用
JP2019532996A (ja) * 2016-11-08 2019-11-14 デリニア，インコーポレーテッド 自己免疫疾患を処置するためのｉｌ−２変異体
US20200164031A1 (en) * 2016-01-15 2020-05-28 Humanitas Mirasole S.P.A. Therapeutic use of inhibitors of t cell activation or stimulation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1878440A1 (en) * 2006-07-13 2008-01-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta cell activator compounds
WO2008127298A2 (en) * 2006-10-24 2008-10-23 Subroto Chatterjee Staphylococcal enterotoxin b peptide compositions and methods of use
EP2367849B1 (en) * 2008-12-05 2017-11-01 ALS Therapy Development Institute Method for the treatment of neurodegenerative diseases
CN102573500A (zh) * 2009-08-06 2012-07-11 纽拉尔图斯制药公司 巨噬细胞相关疾病的治疗
US20170233485A1 (en) * 2014-08-18 2017-08-17 Biogen Ma Inc. Anti-cd40 antibodies and uses thereof
JP7181862B2 (ja) * 2016-10-18 2022-12-01 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 腫瘍浸潤リンパ球および治療の方法
CA3103603A1 (en) * 2018-06-13 2019-12-19 Akron Biotechnology, LLC. Method to prepare therapeutically active aldesleukin highly stable in liquid pharmaceutical compositions
JP2022510377A (ja) * 2018-12-03 2022-01-26 デルマタ・セラピューティクス，エルエルシー 状態の処置のための組成物
CN113795271A (zh) * 2019-03-08 2021-12-14 森德治疗公司 与irgd共施用以治疗癌症的低剂量细胞因子

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130251713A1 (en) * 2000-07-03 2013-09-26 Bristol-Myers Squibb Company Methods for treating juvenile rhumatoid arthritis by administering a soluble ctla4 molecule
US20130295092A1 (en) * 2008-12-05 2013-11-07 Als Therapy Development Institute Method for the Treatment of Neurodegenerative Diseases
JP2013520176A (ja) * 2010-02-19 2013-06-06 ゼンコア インコーポレイテッド 新規ｃｔｌａ４−ｉｇ免疫アドヘシン
JP2014510725A (ja) * 2011-03-11 2014-05-01 アシスタンス ピュブリク−オピトー ドゥ パリ 自己免疫関連障害または炎症性障害の治療のための低用量ｉｌ−２の使用
US20140193908A1 (en) * 2011-07-19 2014-07-10 Philogen S.P.A. Sequential antibody therapy
WO2013041029A1 (en) * 2011-09-23 2013-03-28 Igenimed Pharmaceuticals Inc. Novel soluble ctla4 variants
JP2015530984A (ja) * 2012-08-10 2015-10-29 ロシュ グリクアート アーゲー インターロイキン−２融合タンパク質及びそれらの使用
US20160287671A1 (en) * 2013-06-25 2016-10-06 Icm (Institut Du Cerveau Et De La Moelle Épinière Boosting treg cells for treating alzheimer disease and related disorders
US20200164031A1 (en) * 2016-01-15 2020-05-28 Humanitas Mirasole S.P.A. Therapeutic use of inhibitors of t cell activation or stimulation
JP2019532996A (ja) * 2016-11-08 2019-11-14 デリニア，インコーポレーテッド 自己免疫疾患を処置するためのｉｌ−２変異体
CN109999179A (zh) * 2019-05-08 2019-07-12 山东省分析测试中心 低剂量白介素2用于制备治疗阿尔茨海默病药物中的应用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AM J TRANSPLANT, vol. 12, JPN6026007540, 2012, pages 2313 - 2321, ISSN: 0005807919 *
BRAIN COMMUN, vol. Vol. 2, No. 2, fcaa112, JPN6026007542, 2020, pages 1 - 15, ISSN: 0005807921 *
EBIOMEDICINE, vol. 59, no. 102844, JPN6026007544, 2020, pages 1 - 12, ISSN: 0005807923 *
MOL NEURODEGENER, vol. 15, no. 32, JPN6026007541, 2020, pages 1 - 26, ISSN: 0005807920 *
NEUROL NEUROIMMUNOL NEUROINFLAMM, vol. Vol. 5, No. 4, Article No. e465, JPN6026007543, 2018, pages 1 - 7, ISSN: 0005807922 *

Also Published As

Publication number Publication date
EP4304624A1 (en) 2024-01-17
US20240148827A1 (en) 2024-05-09
MX2023010455A (es) 2023-11-28
EP4304624A4 (en) 2025-02-19
AU2022235091A9 (en) 2023-10-12
WO2022192536A1 (en) 2022-09-15
KR20230169147A (ko) 2023-12-15
AU2022235091A1 (en) 2023-09-21
CA3211627A1 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
EP3689913B1 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
JP5905534B2 (ja) 多発性硬化症を治療する方法
ES2783448T3 (es) Métodos de tratamiento del lupus eritematoso sistémico utilizando un anticuerpo de dominio dirigido contra CD28
JP2016537340A5 (https=)
CN108310376A (zh) 用于治疗类风湿性关节炎的组合物及其使用方法
JP2010132660A5 (https=)
KR20170028441A (ko) 고콜레스테롤혈증이 있는 심혈관 위험이 높은 환자를 치료하는 방법
CN121152807A (zh) 使用抗cd40l抗体治疗多发性硬化症
WO2021126637A1 (en) Methods of treating pancytopenia
JP2024509911A (ja) 疾患の治療のための方法及び組成物
CN117337189A (zh) 用于治疗疾病的方法和组合物
US20250049934A1 (en) DOSING REGIMENS FOR SELECTIVE TREG STIMULATOR RUR20kD-IL-2 AND RELATED COMPOSITIONS
US11400131B2 (en) Multi-peptide composition
WO2026030323A1 (en) Methods and compositions for treatment of disease
HK40033729B (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
HK40033729A (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
KR20210010518A (ko) Il-4r 억제제를 투여하여 아토피성 피부염을 치료하는 방법
HK1227890A1 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
HK1227890B (en) Use of a pcsk9 inhibitor to treat hyperlipidemia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250307

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250526

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260303